VA
MLTX icon

Vident Advisory’s MoonLake Immunotherapeutics MLTX Stock Holding History

Vident Advisory’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Sell
16,473
-1,735
-10% -$31.5K ﹤0.01% 1585
2026
Q1 		$339K Buy
18,208
+2,764
+18% +$45.8K ﹤0.01% 1442
2025
Q4 		$204K Buy
+15,444
New +$182K ﹤0.01% 1550

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vident Advisory's MLTX Position: Q2 2026 in Review

Vident Advisory reduced its MoonLake Immunotherapeutics (MLTX) stake by 9.5% in Q2 2026, selling an estimated $31.5K and leaving 16,473 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Vident Advisory first reported a position in MLTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $339K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Vident Advisory held 16,473 shares of MoonLake Immunotherapeutics worth $321K as of Q2 2026.
  • Vident Advisory sold 1,735 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $31.5K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1585 holding.
  • Vident Advisory first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Vident Advisory's MoonLake Immunotherapeutics position peaked at $339K in Q1 2026.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.